ABSTRACT: Background. Adenoid cystic carcinomas (ACCs) are malignant salivary gland tumors noteworthy for high rates of late failure with limited salvage therapy options. We have previously shown increased Akt signaling is common in ACC and the human immunodeficiency virus (HIV) protease inhibitor nelfinavir (NFV) inhibits in vitro tumor growth by suppressing Akt signaling. This phase II trial was conducted to determine progression-free survival in response to NFV in patients with recurrent/ endstage ACC who have failed standard therapies. Methods. Eligible patients had recurrent or end-stage ACC and measureable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria. NFV was provided at 1250 mg twice daily.
INTRODUCTION
Although relatively rare, accounting for less than 1% of head and neck cancers overall, adenoid cystic carcinoma (ACC) is one of the most common malignant salivary gland tumors and accounts for an estimated 14% of the salivary gland cancers occurring in the United States each year. 1, 2 ACC can arise from both major and minor salivary glands in a variety of head and neck locations, including the parotid and submandibular glands, oral cavity, oropharynx, nasal cavity/paranasal sinuses, and larynx. 3 Primary therapy typically consists of surgical resection and adjuvant radiation therapy. Relative to other head and neck cancers, ACCs are noteworthy for their indolent clinical course and a propensity for late failure as evidenced by recurrence-free survival rates of 65% at 5 years, but only 30% at 15 years. 3 At the time of recurrence, salvage treatment options are often limited by the risk of severe treatment-related morbidity with additional surgery or radiation. Furthermore, response rates with standard chemotherapies are poor, 4 highlighting the need for novel/additional targeted therapies.
In previous work, we have used immunohistochemical techniques to examine the activity of oncogenic cell signaling pathways in a series of 9 paraffin-embedded ACC tissue specimens. We found that 7 of 9 showed strong phosphorylated Akt expression, 5 of 9 showed strong phosphorylated mitogen-activated protein kinase, and 0 of 9 strong epidermal growth factor receptor expression. 5 Although no Akt pathway inhibitors are currently approved for treatment of head and neck cancers, we have previously shown that the human immunodeficiency virus (HIV) protease inhibitor nelfinavir (NFV) can suppress Akt pathway signaling in transformed cell lines, 6 suggesting its potential use as a therapy in the challenging clinical circumstance of recurrent ACC. Subsequent in vitro testing in transformed cells revealed that NFV treatment at drug concentrations achievable in vivo in humans results in decreased Akt pathway activity, decreased tumor cell proliferation, and decreased clonogenic survival relative to controls. 5 Because NFV showed efficacy in inhibiting Akt activity in vitro, and because its safety profile is already well established 7 (making a phase I trial unnecessary), we initiated a phase II study examining the efficacy of NFV therapy in patients with recurrent ACC who have failed standard therapies.
PATIENTS AND METHODS

Study design
The primary objective for this phase II trial was to determine progression-free survival in response to NFV ). Patients with localized and metastatic disease were included in the study.
A screening visit with full medical history and physical, including a complete blood count with differential, serum chemistries, ALT, AST, serum bilirubin, serum creatinine, and pregnancy test (in patients of childbearing potential), were obtained before initiation of NFV therapy. At each subsequent clinic visit, the patient completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30-questions, performance status and vital signs were obtained, and the patient was screened for concomitant medication use. Clinical visits were obtained on a monthly basis at study entry, or sooner as deemed necessary by the treating physician. The interval between visits was lengthened at the discretion of the treating physician. Imaging studies were obtained at mean and median intervals of every 12 weeks after trial enrollment (range, 7.0-14.4 weeks; SD 6 1.78 weeks).
NFV was provided at 1250 mg twice daily (a standard dose used in HIV therapy; Micromedex Healthcare Series; Drugdex System, Greenwood Village, CO) until patients refused further treatment; or developed progressive disease/symptoms, unacceptable adverse events attributed to NFV by the treating physician, or intercurrent illness preventing further treatment administration. Medical adverse events were graded using the Common Terminology Criteria for Adverse Events, version 3.0.
8 Toxicities requiring dose modification were defined as any grade 4 neutropenia, grade 3 neutropenia of more than 21 days, grade 4 thrombocytopenia, grade 3 ALT/AST elevation, any grade 3 metabolic laboratory abnormality lasting more than 7 days, or any grade 3 toxicity not explainable by other causes. In patients who developed a toxicity requiring dose modification, treatment was delayed for a minimum of 1 week. If the toxicity became grade 1 or 0 within 4 weeks off therapy, patients wishing to continue trial participation were allowed to resume NFV starting at a reduced dose (625 mg twice daily), which could later be increased (to a maximum dose of 1250 mg twice daily) at the discretion of the treating physician.
Statistics
Treatment efficacy was determined by progression-free survival, time to treatment failure, and measureable disease response per RECIST (version 1.1) criteria. 9 RECIST assessments were performed by 1 of 2 study authors (M. M. M. or J. M. B.). Best response assessments were based on a minimum time from study entry of 8 weeks. Progression-free survival was defined as the time from study enrollment until disease progression by RECIST criteria or death from any cause. Patients in whom neither outcome had been observed at the time therapy was discontinued were treated as censored for the purposes of data analysis. Time to treatment failure was defined as the time from study enrollment until treatment was discontinued for any reason. Results of a previous phase II clinical trial showed a median progression-free survival of 3.5 months among patients with recurrent or metastatic ACC treated with lapatinib monotherapy. 10 This trial was powered to test the statistical hypothesis that NFV therapy improves median progression-free survival to at least 5.2 months in a similar patient cohort. To test a 1-sided statistical hypothesis at the 0.10 level of significance with a power of 0.80, a minimum enrollment of 30 patients was estimated. Early trial termination was initiated after enrollment of 15 patients when interim analysis showed that no patient met RECIST criteria for a partial or complete response to NFV therapy and a significant number of patients discontinued treatments because of toxicity or poor tolerance.
RESULTS
Patient characteristics
Between October 26, 2009, and February 13, 2012, 15 patients underwent NFV therapy for recurrent ACC at the University of Iowa Hospitals and Clinics. Patient characteristics are listed in Table 1 . Median age of enrolled patients was 52 years (range, 25-77 years). Sixty percent of the patients (9 of 15) were women. Most patients (13 of 15) had primary disease locations in the head and neck, whereas 1 patient had a primary lung location and 1 patient presented with metastatic disease of unknown primary. All patients had failed previous cancer-specific therapy, usually consisting of a combination of surgery (13 patients) and radiation therapy (14 patients), with or without chemotherapy (7 patients).
Progression-free survival
Individual patient treatment characteristics are shown in Table 2 . Of the 15 patients enrolled in the trial, 10 met the progression-free survival analysis endpoint of radiographic disease progression by RECIST criteria. Patients who did not meet this endpoint (n 5 5) were censored from progression-free survival analysis. No patients died during trial participation.
The median duration of NFV therapy was 3.2 months, whereas the median progression-free survival was 5.5 months (lower 95% confidence interval 5 4.4 months, upper bound not estimable; Figure 1 ). The best RECIST response achieved by any patient during participation in the trial was stable disease, which was observed in 7 patients at some point during their trial participation. Among these 7 patients, 2 had documented stable disease at time points beyond 6 months after trial enrollment. No patient achieved a partial or complete response to NFV therapy.
Among the 12 patients who participated in the trial long enough to undergo at least 1 follow-up imaging assessment, 9 showed measureable tumor growth at the first follow-up scan (4 patients who met RECIST criteria for progression and 5 patients who had tumor growth not meeting RECIST criteria; Figure 2 ). Although not meeting RECIST criteria for a partial response, 3 patients showed measureable disease regression at the first follow-up scan after trial entry. Among these 3 patients, 2 ultimately developed progressive disease (at 8.7 and 5.5 months after study entry) and 1 withdrew because of toxicity without undergoing any further imaging assessments on trial.
Toxicity
Five patients experienced grade 3 or higher medical adverse events or toxicities requiring dose modification that ultimately resulted in discontinuation of therapy. These included grade 4 hyponatremia, grade 3 thrombocytopenia, grade 3 dizziness in 1 patient each, and grade 3 liver enzyme elevations in 2 patients. In 3 cases, the patient resumed NFV therapy after a treatment break but ultimately experienced symptom recurrences that led to trial withdrawal. One patient (severe hyponatremia) Abbreviations: KPS, Karnofsky performance status; PFS, progression-free survival; LR, locally recurrent; S, surgery; C, chemotherapy (the number of systemic therapy regimens each patient received before trial enrollment is noted in parentheses); RT, radiation therapy; PD, progressive disease; M, metastatic; X, censored; SD, stable disease. Duration of nelfinavir therapy (treatment duration) and PFS are given in months. FIGURE 1. Progression-free survival for patients undergoing nelfinavir therapy for recurrent adenoid cystic carcinoma (dashes 5 95% confidence interval; tick marks represent censored events). showed improvement in his laboratory measures after holding NFV and receiving medical therapy but was advised not to resume trial participation by his treating physician. The final patient (grade 3 thrombocytopenia) enrolled in hospice care shortly after trial withdrawal and did not undergo follow-up laboratory evaluation. All other patients withdrew from trial participation after disease progression was noted on follow-up imaging. Median time to treatment failure was 3.2 months.
Health-related quality of life data was obtained for 13 of the 15 patients enrolled in the trial. Among these 13 patients, 7 showed worse QLQ-30 Global Health Status Scores at the first follow-up evaluation after trial entry, 2 patients showed no change, and 4 patients showed improved scores. Surprisingly, among the 4 patients who met RECIST criteria for disease progression at the first follow-up imaging evaluation after trial entry, 2 had improved QLQ-30 Global Health Status Scores.
DISCUSSION
Although approved for use in HIV as an antiretroviral therapy, NFV has also shown promise as an antineoplastic agent in a number of preclinical studies. The antineoplastic effect of NFV is thought to be mediated by inhibition of the Akt signaling pathway. We have previously shown that Akt upregulation is common in ACC, and NFV mediated Akt inhibition results in decreased tumor cell survival in vitro. 5 Therefore, we chose to initiate a phase II clinical trial investigating the potential efficacy of NFV in the treatment of ACC patients who have failed traditional surgical, radiation, and/or chemotherapies.
Our results are noteworthy for a large proportion of patients who experienced medical adverse events leading to termination of trial participation. Most of these adverse events, including liver enzyme elevations, dizziness, and thrombocytopenia, have also been observed among patients with HIV undergoing NFV therapy. 11, 12 In addition, although hyponatremia is not commonly reported among patients with HIV undergoing NFV therapy, diarrhea is a common side effect, which may have been a contributing factor to the severe hyponatremia that resulted in trial termination for 1 participant in our trial.
In addition to our own work, there have been a number of preclinical studies demonstrating antitumor effects of NFV in dozens of cancer cell lines representing a broad range of cancer subtypes, including hepatocellular, breast, head and neck, and prostate carcinomas; multiple myeloma; glioblastoma multiforme; liposarcoma, and others. 6, [13] [14] [15] [16] [17] [18] In spite of these promising preclinical studies, the efficacy of NFV as a cancer monotherapy has, to our knowledge, never been demonstrated in a clinical trial. Likewise, a large retrospective multicenter study of patients with HIV (an at risk population for multiple cancers) undergoing NFV therapy did not show significantly different cancer incidence rates compared to non-NFV treated patients. 19 These results should not be interpreted to mean that NFV is ineffective in cancer therapy. Indeed, most of the aforementioned preclinical studies show that NFV has greater impact as a radio or chemosensitizer, rather than a single modality intervention; and several phase I clinical trials have shown promising results using NFV in combination therapy regimens among patients with non-small cell lung and pancreatic cancers, 20, 21 spurring additional phase II trials that are currently underway.
Not surprisingly, the medical literature regarding NFV in cancer therapy parallels that generally reported with other Akt pathway inhibitors. A number of PI3 kinase/ Akt pathway inhibitors have been tested, or are currently under investigation in phase I/II clinical trials, and several have shown some efficacy in treating a number of cancer subtypes. 22 Patients with PI3 kinase mutations seem to derive the most benefit from Akt axis inhibition as evidenced by results of a clinical study at the MD Anderson Cancer Center in which response rates of 35% were observed, compared to rates of only 6% among patients without PI3 kinase mutations. 23 As with NFV, several reports suggest that combination therapies are more effective than Akt inhibitors as monotherapy, particularly given that Akt signaling is thought to play a key role in mediating resistance to chemotherapy, radiation, and hormonal anticancer therapies. 22, 24 Here, we report the results of NFV as a cancer therapy in the specific setting of recurrent ACC. Despite good preclinical evidence, we were unable to demonstrate a clinically meaningful improvement in patient outcomes in response to NFV in the setting of ACC that has failed previous therapy. Our observed median progression-free survival (5.5 months) does represent a slight improvement relative to a previously published progression-free survival rate of 3.5 months in response to lapatinib monotherapy 10 ; however, this finding is not unexpected considering the favorable selection criteria used in our study design. In addition, the frequency of RECIST assessment was every 8 weeks in the previous study, whereas, in our study, it was assessed at a median interval of 12 weeks. This difference in methods may have artificially prolonged the progression-free survival observed in our work.
Several patients in our study did achieve a limited duration of radiographic stable disease by RECIST criteria (less than a 20% increase in tumor size), 2 patients with documented stable disease for more than 6 months. However, any such positive effect is likely of minimal practical clinical significance for the following reasons: (1) no patient achieved a RECIST partial or complete response to therapy at any point during trial participation; (2) 9 of 12 assessable patients showed radiographic evidence of tumor growth at the first follow-up scan after trial enrollment; (3) a large proportion of patients in our trial (33%) experienced medical adverse events leading to early trial termination and a median time to treatment failure of just 3.2 months; and (4) our findings do not represent an improvement over previously published reports of ACC response to palliative treatment with a more traditional chemotherapy regimen of cisplatin and 5-fluorouracil. 25 As such, our results are consistent with previous clinical and preclinical studies demonstrating that Akt pathway inhibitors in general, and NFV specifically, are minimally effective as cancer monotherapies. This does not rule out their potential utility in combination therapy regimens, either with radiation, conventional chemotherapy, or other targeted therapies. We suggest that such an approach would be the most appropriate strategy for future clinical trials investigating NFV and other Akt pathway inhibitors in the treatment of ACC.
